Bristol-Myers Squibb's Breyanzi was approved by the U.S. Food and Drug Administration, making it the first and only chimeric antigen receptor T-cell therapy for adult patients with recurrent or refractory marginal lymphoma.

Bristol-Myers Squibb's Breyanzi was approved by the U.S. Food and Drug Administration, making it the first and only chimeric antigen receptor T-cell therapy for adult patients with recurrent or refractory marginal lymphoma.